On the basis of superior outcomes from electrochemogene therapy (ECGT) compared with electrochemotherapy in mice, we determined the efficacy of ECGT applied to spontaneous canine neoplasms. Intralesional bleomycin and feline interleukin-12 DNA (fIL-12 DNA) injection combined with translesional electroporation resulted in complete cure of two recurrent World Health Organization stage T 2b N 0 M 0 oral squamous cell carcinomas (SCCs) and one T 2 N 0 M 0 acanthomatous ameloblastoma. Three remaining dogs, which had no other treatment options, had partial responses to ECGT; one had mandibular T 3b N 2b M 1 melanoma with pulmonary and lymph node metastases; one had cubital T 3 N 0 M 1 histiocytic sarcoma with spleen metastases; and one had soft palate T 3 N 0 M 0 fibrosarcoma. The melanoma dog had decrease in size of the primary tumor before recrudescence and euthanasia. The histiocytic sarcoma dog had resolution of the primary tumor, but was euthanized because of metastases 4 months after the only treatment. The dog with T 3 N 0 M 0 fibrosarcoma had tumor regression with recrudescence. Treatment was associated with minimal side effects and was easy to perform. It was associated with repair of bone lysis in cured dogs, it improved quality of life of dogs with partial responses and extended overall survival time. ECGT seems to be a safe and resulted in complete responses in SCC and acanthomatous ameloblastoma.
Introduction
Electroporation (EP) is the application of a series of square-wave electrical pulses to increase cell permeability and allow movement of molecules into cells. Several recent reviews describe the application of this technique to gene [1] [2] [3] [4] [5] and drug therapy. 4, [6] [7] [8] [9] Over the past 15 years, EP has become a common technique for introducing large molecules into cells, both in vitro and in vivo.
Interleukin (IL)-12 treatment can have a dramatic antitumor effect on a variety of neoplasms. [10] [11] [12] [13] [14] [15] Both innate resistance and adaptive immunity are affected by IL-12-mediated antitumor resistance. Interferon-g and other cytokines induced by IL-12 either directly, or indirectly through other cytokine signaling, have both direct toxic effects on the tumor cells, and potent antiangiogenic activity on tumor neovasculature. The action of IL-12 in adaptive immunity relies on its ability to trigger or augment Th1 and cytotoxic T lymphocyte responses. Thus, IL-12 has a potent adjuvant activity in cancer therapy, and in vivo EP delivery of genes or electrogene therapy (EGT) has been described in numerous tumor-bearing murine models and in early human trials. 16, 17 In these studies, IL-12 EGT eradicates tumors and induces long-term antitumor memory, but is unable to eradicate large tumors. 17 Bleomycin (BLM), an antitumor antibiotic, causes breaks in double-stranded DNA and releases free radicals that cause cellular oxidant damage. 18 Delivery of BLM by local electrochemotherapy (ECT) is an ideal way to increase efficacy while reducing potential toxic side effects. Once BLM enters tumor cells during ECT, it becomes sequestered because of its large size and lack of transmembrane transporters. This sequestered site prevents nontarget organ toxicity and allows specific targeting to the local EP site. In experimental animal models, delivery of BLM by intratumoral ECT consistently eradicates large tumors but often fails to extend survival time over standard therapy. EP delivery of chemotherapeutics has been described in animals for the treatment of squamous cell carcinoma (SCC) in cats 19 and a variety of cutaneous and subcutaneous tumors in cats, dogs and horses. 9 BLM ECT has also been well tolerated in humans with between 9 and 100% complete response rates depending on the technique used. 20 In fact, the European medical community has embraced ECT for many years, as evidenced by the results of the European Standard Operating Procedures of Electrochemotherapy trials completed in 2003. These trials demonstrated that ECT was not only safe and effective, but also efficacious for local control of a variety of tumors. 21 Two of the limitations of ECT are that it is currently suitable only for local treatment of superficial tumors, and it only targets the primary tumor. 21 Thus, the combination of BLM, which is able to eradicate large primary tumors, and the gene for IL-12, which can induce antitumor immunity, seems ideally suited for treatment of most neoplasia that is accessible to local treatment. In fact, we and others have previously demonstrated that this combination can successfully eradicate and prevent recurrence of mammary cancer and melanoma in mouse tumor models. 17, 22 In addition to being efficacious, this treatment seems to be well tolerated, has minimal side effects, preserves tissue architecture and could be easily adapted to clinical use. However, this combination has not been tested in large animals bearing naturally occurring tumors, nor has it been used in humans at this point. To determine whether experimental results translate into positive clinical results, we used electrochemogene therapy (ECGT) to treat six client-owned dogs with a variety of tumors.
Materials and methods

Selection of naturally occurring tumor-bearing dogs
Privately owned dogs that were referred to the Cancer Treatment Unit of the Louisiana State University's Veterinary Teaching Hospital and Clinics were selected for the study from 2004 to 2008. Apart from having histologically confirmed neoplastic disease, inclusion criteria included the absence of overt heart, renal or other life-threatening illness. Dogs were staged by obtaining a thorough anamnesis, physical examination, complete blood cell count, serum biochemistry profile, urinalysis, electrocardiogram, thoracic radiographs (three-view metastasis check) and abdominal ultrasound if indicated. In addition, two of the dogs had computerized tomography (CT) scanning of the skull to gauge the degree of local tumor invasion and bone lysis.
In vitro IL-12 augmented cytotoxicity determination An SCC cell line (SCCVII) was transfected with either two micrograms fIL-12 DNA or control DNA by in vitro EP, grown for 24 h, and conditioned medium was collected. DNA was prepared using endotoxin-free preparation kits (Qiagen, Germantown, MD) using the standard protocol provided by the manufacturer. Leukocytes were harvested from pretreatment blood samples obtained from the second SCC-bearing dog. Leukocytes (5 Â 10 5 ) were then added to 1.5 ml of the conditioned medium and incubated for 18 h at 37 1C. Conditioned leukocytes were then mixed in a 50:1 ratio with fluorescent-labeled canine osteosarcoma target cells (D17) and incubated for 24 h at 37 1C. The number of remaining fluorescent cells (live cells) per microliter were then counted and compared with numbers remaining with control DNA.
Imaging
Except for abdominal ultrasound on the dog with histiocytic sarcoma, dogs were anesthetized for CT scans. An intravenous catheter was placed in the cephalic vein and maintenance fluids were delivered during anesthesia. Dogs were premedicated with various combinations of anxietolytic, analgesic and parasympatholytic drugs, induced with propofol, intubated and maintained on isoflurane in oxygen. Hemoglobin oxygen saturation, blood pressure and electrocardiography were monitored during anesthesia.
For staging using thoracic radiographs, ventrodorsal, left lateral and right lateral radiographs were obtained using digital radiography equipment (Siemens Medical Solutions, Malvern, PA) and were evaluated by boarded veterinary radiologists. For CT scans of the first SCC dog, a single-slice spiral CT scanner (Picker PQ-5000, Picker-now GE Healthcare, Waukesha, WI) was used. For the second SCC dog, a 16-slice volume CT scanner (Lightspeed VCT, GE Healthcare) was used. Abdominal ultrasound was also performed by a boarded veterinary radiologist and used a Logiq 9 ultrasound machine (GE Healthcare).
Other diagnostics
For clinicopathological data, routine jugular phlebotomy and collection into EDTA blood and serum separator tubes were used to determine complete blood counts and serum chemistry analyses. Blood was run on an automated ADVIA 120 hematology analyzer with multispecies software (Bayer, Fernwald, Germany) and blood smear differential was confirmed manually. Serum was run on an Olympus AU640e automated chemistry analyzer (Olympus, Center Valley, PA). Urine was obtained by cystocentesis and routine urinalyses consisted of determining urine specific gravity, urine dipstick analytes and sediment examination. In case of the histiocytic sarcoma dog, this was followed by routine urine culture and sensitivity.
For confirmation of tumor type, excision biopsies from the primary tumor were obtained surgically under anesthesia and were placed in 10% neutral-buffered formalin. After being fixed, tissue was cut-in, paraffin embedded, sectioned at 3 mm, adhered to slides, stained with hematoxylin and eosin, cover-slipped and evaluated by boarded veterinary pathologists.
Treatment
An intravenous catheter was placed in the cephalic vein and maintenance fluids were delivered during anesthesia. Dogs were premedicated with various combinations of anxietolytic, analgesic and/or parasympatholytic drugs, induced with propofol, intubated and maintained on isoflurane in oxygen. Hemoglobin oxygen saturation, blood pressure and electrocardiography were monitored during anesthesia. Between 0.5 and 2.0 IU BLM (Bleo, Teva Parenteral Medicines, Irvine, CA) and 150-400 mg fIL-12 DNA were injected parenterally into the center of the mass at doses of 1-2 ml of 0.45% NaCl, immediately followed by insertion of a hexagonal array of six-needle electrodes (Inovio Biomedical, Blue Bell, PA) surrounding the injection point (translesionally) and EP. The only exception was the first case of SCC in which simple caliper electrodes were used to deliver the pulses. Two 20 ms 400 V cm -1 electrical pulses were administered 100 ms apart using an ECM 830 electroporator (BTX, Genetronics-now Inovio Biomedical). Additional treatments occurred X10 days after the first. The number of treatments varied from one to three, and the study was approved by the Institutional Review Board of the Louisiana State University School of Veterinary Medicine.
Response to treatment was evaluated through recheck examinations, tumor measurement and gross characterization, communication with the pet's owner, follow-up complete blood counts and serum biochemistry profiles, and in two cases, with follow-up CT scans. Complete response is defined as the disappearance of all measurable tumors for 21 days and partial response was defined as 450% reduction in measurable tumor for 21 days. Lack of measurable tumor for 48 months was characterized as a cure for this study.
Results
The fIL-12 depicted in Figure 1a provided by Dr Stephen Dunham (University of Nottingham, UK) was chosen because of the lack of canine IL-12 availability. There is 91% homology between the canine and feline IL- 12, 23 suggesting that the fIL-12 should be functional on canine cells. To confirm this assumption, the biological ability of fIL-12 to activate canine mononuclear cells was determined. Canine leukocytes activated by fIL-12 induced significantly more (Po0.05) canine target tumor cell death when compared with control DNA (Figure 1b) .
All dogs were treated with combinations of BLM and fIL-12 with dosages extrapolated from those used in mice. 17 The dose of BLM and Il-12 DNA was often divided between areas of the tumor receiving EP. For each cm 2 of tumor at its maximum cross-sectional area (on the basis of CT or caliper measurements), 0.5 IU of BLM and 150 mg of fIL-12 DNA were used.
All tumors were examined histologically to confirm histopathology diagnoses and extent of lesions and/or metastatic potential. Representative photomicrographs of available biopsy samples are depicted in Figure 2 . As noted previously, the tumors treated represented a range of carcinomas and sarcomas, and all were diagnosed by boarded pathologists. Noteworthy is the fact that tumor emboli were noted within lymphatics in the biopsy from the first dog with SCC. Both the histiocytic sarcoma and fibrosarcoma were considered grade 3 or high-grade softtissue sarcomas and carried a poor prognosis. 24 The melanoma was also a high grade, given its high mitotic rate, poor differentiation, and diagnosis of lymph node and pulmonary metastases. Regardless of the tumor type and anatomic location, all tumors had clinical response to ECGT. Furthermore, treatment in all cases was associated with minimal side effects. The most significant side effect was 48 h of diarrhea for the dog with metastatic melanoma, but this dog had numerous other medical problems and showed marked stress (aggression), making it difficult to directly link the diarrhea to ECGT. Clinicopathological data remained essentially unchanged after treatment for most dogs (Table 1) . Only the dogs with histiocytic sarcoma and metastatic melanoma had clinicopathologically significant abnormalities. In the dog with histiocytic sarcoma, its bacterial cystitis resolved during treatment and there was no significant progression of its cholestasis or hypercholesterolemia based on serum chemistries. In the dog with melanoma, alkaline phosphatase increased and was thought to represent increasing primary tumor bone involvement or cholestasis; this dog's neutrophilic leukocytosis also progressed slightly and was thought to be related to increased necrosis and ulceration of the primary tumor. It is worthwhile noting that both these dogs had significant changes before treatment; therefore, Bleomycin/IL-12 electrochemogene therapy in dogs SD Reed et al it is not thought that ECGT had any role in the progression of preexisting disease.
Of the six dogs treated, three had complete responses and three had partial responses. The first dog (with maxillary SCC) treated had a complete response. This dog was the only dog to receive BLM/IL-12 ECGT using caliper electrodes as performed in tumor-bearing mice. 17 Morphologically and on CT scan, this dog had clear bone lysis and a large tumor initially (Figure 3a) , whereas after the second treatment, visible tumor was eradicated. After 6 months, the primary lesion had healed and much of the associated bony lysis had been repaired (Figure 3b) . Compared with surgery and radiation therapy, this dog's treatment was without side effects and easily accomplished Abbreviations: Alb., albumin; ALP, alkaline phosphatase; chol., cholesterol; F, female; FS, female spayed; M, male; neut., neutrophils ( Â 10 3 per 100 ml); plat., platelets Â 10 3 per 100 ml; NSF, no significant findings; SCC, squamous cell carcinoma; TB, total bilirubin; TP, total protein; UC, urine culture; WBC, white blood count ( Â 10 3 per 100 ml). Bleomycin/IL-12 electrochemogene therapy in dogs SD Reed et al within a short period of time. This dog remains tumor free almost 5 years later ( Table 2) . The second dog treated also had a complete response. This dog was the first to receive ECGT using a six-needle array electrode (as did all subsequent dogs). CT images taken initially for this dog with mandibular SCC demonstrate marked malocclusion and tumor invasion into adjacent bone (Figure 4a ). By the time the second CT images were taken 1.5 months after the last treatment,
Pre-treatment
Post-treatment Bleomycin/IL-12 electrochemogene therapy in dogs SD Reed et al most of the bony lysis and much of the occlusal changes had resolved (Figure 4b ). Compared with surgery and radiation treatment, this dog experienced minimal side effects from ECGT. Aside for a single day of lethargy and decreased appetite, no side effects were noted. This dog remains tumor free almost 3 years later ( Table 2 ). The dog with acanthomatous ameloblastoma is our most recent success (Figure 5a ). After the initial diagnosis, this dog's owners were offered either segmental mandibulectomy or radiation therapy. Although both these options offer a high probability of cure, they are associated with significant side effects. In case of surgery, the dog would have had significant orthopedic pain, the chance of surgical complications, and would have had less desirable cosmetic and functional results. Radiation would have required frequent treatments, numerous periods of anesthesia and the potential for radiation side effects. As can be seen from the photograph taken at the time of the last treatment (Figure 5b) , the tumor was completely eradicated with ECGT, avoiding many of the complications associated with surgery and radiation therapy. The area of gingival erosion depicted in Figure 3b subsequently resolved completely leaving no residual tissue damage. After 9 monthsr, this 10-year-old dog remains tumor free ( Table 2) .
The remaining dogs, which were presented because they were thought to have no other treatment options (were not candidates for surgery, chemotherapy or radiation therapy), had partial responses to ECGT. The dog with histiocytic sarcoma had marked enlargement of the left cubital joint associated with the primary tumor and poorweight-bearing lameness (Figure 6a ). After treatment, the primary tumor was eradicated and lameness had improved markedly (Figure 6b ). Post-treatment nodules present were thought to represent scar tissue from the biopsy procedure, and the diameter of the joint was reduced by 1.5 cm. Although not confirmed histologically, the size of the joint in comparison with the contralateral cubital joint was the same suggesting complete resolution of the primary tumor. Although the improvement in this dog's ambulatory ability increased her quality of life, she ultimately was euthanized because of complications from splenic metastases.
Both the dogs with metastatic melanoma and with fibrosarcoma had an initial reduction in tumor size by 450% after ECGT and therefore were also considered partial responders. In case of the dog with melanoma, this 16-year-old dog had progressive neoplastic disease and numerous other medical problems that necessitated euthanasia. The dog with fibrosarcoma also responded initially, but had rapid recurrence and the owner declined further treatment.
The effect of treatment on metastatic disease was not determined. Both dogs with metastatic disease before treatment were ultimately euthanized because of complications either associated with their metastases or with recurrence of the primary tumor. Generalizations regarding the type of tumors amenable to ECGT were also difficult given the small number of dogs treated. As is true with most neoplasia therapies, dogs with advanced metastatic neoplasia seem to be poor candidates for ECGT. At least two types of invasive oral neoplasms, SCC and acanthomatous ameloblastoma, responded well to treatment. Table 2 summarizes the clinical findings and outcomes for five of the dogs treated. The sixth dog (not included in this table), a dog with fibrosarcoma of the soft palate, had initial tumor regression with rapid recrudescence after a single treatment and owners terminated their participation in this study.
Discussion
As noted by several authors, 25 using client-owned dogs for clinical investigation of novel cancer therapies offers several advantages over mice and humans. Compared with humans, dogs have similar anatomy and physiology; they often share the same environment as humans; they naturally develop cancers sharing many characteristics with human cancers, the canine genome has been sequenced; and cancers in dogs grow over long periods of time, yet their growth occurs over a short enough time period to be useful in evaluating new therapies. Dogs also share many of the intraindividual variations that humans do, including varied genetic constitution, varied immune a b 25 From this series of treatments in dogs with spontaneous neoplasms and varied genetic makeup, environmental conditions, nutrition and husbandry, we can conclude that the ECGT was well tolerated and had minimal side effects. In addition, the treatments themselves can be easily accomplished with o15 min of anesthesia. Although not particularly painful, humans receiving EP describe uncomfortable muscle twitching; this discomfort combined with the need to access poorly accessible oral sites necessitates general anesthesia.
Electrochemogene therapy resulted in disease-free intervals of 48 months in three tumors (considered a cure in this study); two of which had recurred after attempts at surgical resection before receiving this ECGT. Two of these tumors were SCCs, which have previously been shown to respond to BLM ECT without gene therapy; 9 however, the period of follow-up was much less than the five cancer-free years that we report here. We were unable to evaluate whether these dogs would have been cured with BLM ECT alone, but theoretically, the augmentation with IL-12 gene therapy should help stimulate immune surveillance/memory and prevent recurrence as we found in mice. 17 Acanthomatous ameloblastoma has not previously been reported to be ECT sensitive; however, the lack of control subjects did not allow us to compare ECT with ECGT for this tumor either.
The dog with fibrosarcoma did not receive a full series of treatments. This dog's partial response to therapy suggests that fibrosarcomas may be partially responsive to this treatment modality. In the two dogs with advanced metastatic neoplasia, ECGT enhanced the dogs' quality of life before euthanasia; the effect of ECGT on metastatic disease was not determined. Both these dogs were not deemed to be candidates for surgery, radiation or chemotherapy because of their advanced disease; thus, ECGT offered a safe, relatively noninvasive method of local tumor control without the side effects associated with conventional cancer therapies.
In humans, the rates of complete response after onceonly treatments of single-agent, BLM ECT is reported to be between 9 and 100% depending on the technique used. 20 EGT of IL-12 has also reached phase I clinical trials in humans and has had similar positive results. In the first trial of gene transfer using EP in humans, the therapy was deemed, 'safe, effective, reproducible and titratable.' 16 Moreover, IL-12 EGT without any other therapy gave complete regression of nonelectroporated distant metastases in 10% of the subjects and produced disease stabilization or partial response in an additional 42%. 16 Although impressive, if these therapies were combined, as in our study, the responses should improve significantly based on our findings in dogs and mice. 17 
Conclusions
Given the previous results achieved with experimentally induced tumors in mice 17 and the encouraging responses achieved in three of the dogs in this study, ECGT offers a promising new approach to simple, relatively noninvasive tumor therapy with minimal side effects in dogs. Furthermore, ECGT may also be applicable to other species with readily available species-specific IL-12 DNA. These early applications support further research and treatment of a variety of neoplasms in dogs, and offer great promise for other species, including humans.
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